SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today affirmed its commitment to re-acquire GRAIL, a healthcare company focused on multi-cancer early detection. “This acquisition is ...
WASHINGTON, June 5 (Reuters) - Illumina (ILMN.O), opens new tab on Monday filed an appeal against a Federal Trade Commission (FTC) order, demanding that it divest ...
Battered by more than three years of opposition from authorities in the United States and Europe—most recently an unfavorable federal appeals court decision on Friday—Illumina said it will divest ...
On June 3, 2024, Illumina’s (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Grail was planning an IPO before ...
Illumina's stock has rebounded 25% since October 2023, despite underwhelming revenue growth and challenges with the NovaSeq X platform and macro headwinds. The company faces issues with the adoption ...
Less than 24 hours after biotech giant Illumina said it would divest early cancer detection firm Grail, activist investor Carl Icahn published a letter announcing he’s ready to do battle against the ...
As recently appointed CEO Jacob Thaysen, PhD, prepares to address the J.P. Morgan 42 nd healthcare Conference in San Francisco on Tuesday morning, Illumina (ILMN) investors and analysts will be among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results